Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Global Value Dossier

- PMLiVE

Mastering Asynchronous Meetings: Open-Ended Questions – Impetus Digital Tip 1

Unlock the potential of asynchronous virtual meetings with the first tip from our "Top 10 Tips for Optimizing Asynchronous Virtual Meetings".

Impetus Digital

- PMLiVE

A new campaign to welcome and celebrate neurodiversity across the UK healthcare communications industry

THINKING DIFFERENT This Neurodiversity Celebration Week (18 to 22 March) the Healthcare Communications Association (HCA), Fox&Cat, and The ADHD Foundation have joined forces to launch a new campaign to help...

Fox&Cat

Meet us at ISPOR

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Mtech Access

- PMLiVE

Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

- PMLiVE

Gates Medical Research Institute initiates phase 3 study of tuberculosis vaccine candidate

According to WHO, the infectious disease was estimated to affect 10.6 million people in 2022

- PMLiVE

Researchers reveal imaging technology could help diagnose and treat bowel cancer

Affecting over 250,000 people, bowel cancer is the fourth most common cancer in the UK

- PMLiVE

Early strategic planning: how to get ahead of the curve

By James Aird and Sarah Theobald

AMICULUM

- PMLiVE

Thinking Different – a new campaign to welcome and celebrate neurodiversity across the UK healthcare communications industry

It is estimated that there are 50% more neurodivergent practitioners working in creative sectors, like healthcare communications, than in the general population

- PMLiVE

AstraZeneca to acquire Fusion Pharmaceuticals in deal worth $2.4bn

The transaction includes a potential new treatment for metastatic castration-resistant prostate cancer

- PMLiVE

Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia

The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL

- PMLiVE

FDA approves Orchard’s Lenmeldy gene therapy for metachromatic leukodystrophy

The rare genetic disease is estimated to affect one in every 40,000 people in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links